Regorafenib-resistant KIT mutants do not bind regorafenib

Stable Identifier
R-HSA-9669870
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Regorafenib-resistant KIT mutants do not bind regorafenib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Regorafenib is used as a secondary therapeutic in cases of imatinib-resistant cancers with KIT mutations. Its effectiveness depends on the position of the secondary mutation. Regorafenib is effective in imatinib-resistant tumors carrying secondary mutations in exon 14 (gatekeeper) and most secondary mutations encoded by exons 17 and 18 (activation loop) (Yeh et al, 2017; Miyake et al, 2018; Serrano et al, 2019a,b; reviewed in Roskoski, 2018; Klug et al, 2018).
Literature References
PubMed ID Title Journal Year
28487491 A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

Tzen, CY, Chen, MH, Chen, YY, Yang, CY, Yen, CC, Yeh, CN, Chen, JS, Chen, LT

Oncotarget 2017
29334307 Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Miyake, K, Momiyama, M, Eilber, FC, Murakami, T, Russell, T, Miyake, M, Chishima, T, Li, Y, Singh, A, Matsuyama, R, Zhang, Z, Igarashi, K, Elliott, I, Hoffman, RM, Kiyuna, T, Kawaguchi, K, Nelson, SD, Hiroshima, Y, Endo, I

Cell Cycle 2018
29704617 The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
30792533 Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Heinrich, MC, Ketzer, J, Bauer, S, Zhu, M, Presnell, A, Raut, CP, George, S, Mannan, AM, Serrano, C, Yu, C, Sicinska, E, Tao, DL, Rubin, BP, Fletcher, JA, Mariño-Enríquez, A, Demetri, GD, Eilers, G, Czaplinski, JT, McKinley, A

Br. J. Cancer 2019
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Heinrich, MC, Kent, JD, Klug, LR

Pharmacol. Ther. 2018
12181401 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Joensuu, H, Silberman, SL, Capdeville, R, Peng, B, Heinrich, MC, Singer, S, Roberts, PJ, Blanke, CD, von Mehren, M, Eisenberg, B, Fletcher, JA, Demetri, GD, Kiese, B, Corless, C, Silverman, SG, Fletcher, CD, Druker, BJ, Janicek, M, Dimitrijevic, S, Tuveson, DA, Van den Abbeele, AD

N. Engl. J. Med. 2002
31471313 Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

Morgan, JA, Phallen, J, Paweletz, CP, Kuang, Y, George, S, Leal, A, Barysauskas, CM, Serrano, C, Triplett, O, Fletcher, JA, Wagner, AJ, Mariño-Enríquez, A, Demetri, GD, Velculescu, VE

Clin. Cancer Res. 2019
Participants
Input
Participates
as an event of
Normal reaction
KIT binds type II TKIs (Homo sapiens)
Functional status

Loss of function of regorafenib-resistant KIT mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-04-01)
Reviewed
Pilco-Janeta, D  (2020-03-13)
Serrano, C  (2020-03-13)
García-Valverde, A  (2020-03-13)
Created
Rothfels, K  (2019-12-03)
Cite Us!